SG Americas Securities LLC Acquires 7,130 Shares of HUTCHISON CHINA/S (HCM)
SG Americas Securities LLC grew its holdings in HUTCHISON CHINA/S (NASDAQ:HCM) by 65.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,949 shares of the company’s stock after purchasing an additional 7,130 shares during the quarter. SG Americas Securities LLC’s holdings in HUTCHISON CHINA/S were worth $549,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of HUTCHISON CHINA/S by 375.0% during the 3rd quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock worth $1,040,000 after acquiring an additional 25,500 shares in the last quarter. Deutsche Bank AG raised its stake in shares of HUTCHISON CHINA/S by 300.9% during the 4th quarter. Deutsche Bank AG now owns 129,822 shares of the company’s stock worth $2,995,000 after acquiring an additional 97,440 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of HUTCHISON CHINA/S by 0.6% during the 4th quarter. Baillie Gifford & Co. now owns 198,959 shares of the company’s stock worth $4,594,000 after acquiring an additional 1,213 shares in the last quarter. Barclays PLC bought a new position in shares of HUTCHISON CHINA/S during the 4th quarter worth approximately $807,000. Finally, Bank of New York Mellon Corp bought a new position in shares of HUTCHISON CHINA/S during the 4th quarter worth approximately $1,509,000. Institutional investors and hedge funds own 18.61% of the company’s stock.
HCM has been the subject of several recent analyst reports. Deutsche Bank initiated coverage on shares of HUTCHISON CHINA/S in a research note on Monday, March 4th. They set a “buy” rating and a $26.82 price objective for the company. Zacks Investment Research downgraded shares of HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. BidaskClub downgraded shares of HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a research report on Thursday, February 7th. Finally, HSBC began coverage on shares of HUTCHISON CHINA/S in a research report on Wednesday, March 27th. They set a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. HUTCHISON CHINA/S has an average rating of “Buy” and a consensus price target of $26.82.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Recommended Story: Diluted Earnings Per Share
Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.